U.S. Metals and Mining Stock News

If you are wondering whether Lennar's share price reflects its real worth, this article will walk through what the current market price might be implying about the company's value. Lennar's stock closed at US$104.30, with returns of a 6.9% decline over 7 days, a 7.3% decline over 30 days, roughly flat at 0.1% year to date, and a 15.8% decline over 1 year, while the 3 year and 5 year returns sit at 19.6% and 33.5% respectively. Recent share price moves have kept Lennar on the radar for...

Tradeweb Markets (NasdaqGS:TW) reported record trading activity in February 2026. Total trading volumes for the month showed strong year over year growth across several asset classes. Activity was led by U.S. and European government bonds, credit, ETFs, and money markets. Management linked the surge to broader client adoption, market driven trading activity, and upgrades to electronic trading protocols. For anyone tracking Tradeweb Markets, the latest volume update provides more detail on...

BioNTech is shifting focus from a pure COVID-19 vaccine player to a broader biotech company with a heavier tilt toward oncology. The company has acquired Biotheseus and entered a new cancer focused collaboration with Bristol Myers, expanding its pipeline beyond infectious diseases. These moves mark a change in how BioNTech allocates capital and positions its portfolio for future therapeutic areas. For investors watching NasdaqGS:BNTX, the story is now less about a single COVID-19 product...

Monte Rosa Therapeutics recently reported updated, positive Phase 1/2 data showing that its investigational GSPT1 degrader MRT-2359, combined with enzalutamide, was well-tolerated in heavily pretreated metastatic castration-resistant prostate cancer patients, and the company now plans to move the regimen into Phase 2 development. The ASCO GU 2026 presentation highlights Monte Rosa’s progress in applying its molecular glue degrader platform to a hard-to-treat, AR‑mutated prostate cancer...

Arcosa (NYSE:ACA) announced the sale of its barge business and is shifting its focus toward construction materials and engineered structures. The move is aimed at concentrating resources on U.S. infrastructure and power related businesses that management views as core to the company. Arcosa, trading at $111.28 at the last close, is coming off a strong longer term stretch, with the stock up 37.0% over the past year and 87.8% over three years. The company is also ahead 76.5% over five years,...

Brown-Forman Corporation recently reported fiscal third-quarter 2026 results, with sales of US$1,396 million and revenue of US$1,056 million, while also completing a US$400.21 million share repurchase program that retired 14,053,649 shares, or 2.99% of its share count. Amid flat to softer year-to-date revenue and earnings, management reiterated expectations for a low-single-digit organic sales decline and highlighted ongoing macro, trade, and developed-market demand pressures, even as...

If you are wondering whether Semtech's recent run means the stock is still reasonably priced or already stretched, you are not alone. The share price last closed at US$87.08, with a 1 year return of 169.3% and a year to date return of 15.7%, even though the last 7 days and 30 days show declines of 3.8% and 0.6% respectively. That mix of strong longer term gains and recent softness often follows shifts in how investors view the company's risk and opportunity, or how they react to new...

UPS (NYSE:UPS) is shifting its core model toward an AI driven logistics platform focused on automation and higher margin business customers. The company is repositioning from a traditional shipping provider to a more data centric, technology led operations model. The transition is aimed at reshaping how UPS manages its network, allocates capacity, and serves enterprise level demand. For you as an investor, this move touches the core of what UPS is: a global logistics company that...

Comments from McEwen (NYSE:MUX) chair and CEO Rob McEwen at the PDAC 2026 conference have put fresh attention on mining equities, as he pointed to a potential investor shift toward metals like gold and copper. See our latest analysis for McEwen. McEwen's comments at PDAC come at a time when the share price has pulled back in the short term, with a 1 day share price return showing a 6.39% decline and a 7 day share price return showing a 14.77% decline. However, the 90 day share price return of...

Why Entergy (ETR) Is On Investors’ Radar Today Entergy (ETR) has drawn fresh attention after recent share price moves, with the stock closing at US$105.48. That has investors rechecking its recent returns, earnings profile, and current valuation. See our latest analysis for Entergy. While Entergy’s share price slipped 0.95% over the last session and is roughly flat over the past week, the 30 day share price return of 8.35% and year to date share price return of 12.38% sit alongside a 1 year...

In recent days, Toast, Inc. has been highlighted as a core software and payments layer for the restaurant industry, now supporting 156,000 locations and processing US$51.50 billion in gross payment volume, while attracting increased attention from investors following sector volatility and commentary on enterprise software resilience amid AI adoption. What stands out is how Toast’s unified platform and expanding enterprise and international footprint are reinforcing its role as an embedded...

HA Sustainable Infrastructure Capital recently redeemed all US$450,000,000 of its 8.000% senior notes due 2027, using proceeds from new 6.000% green senior unsecured notes due 2036 and 7.125% green junior subordinated notes due 2056. This refinancing not only lengthens the company’s debt maturity profile but also aligns its funding base more closely with sustainability-focused investment projects. Next, we will examine how replacing higher‑coupon 2027 senior debt with longer‑dated green...

If you are wondering whether Wealthfront's current share price reflects its true worth, you are not alone; many investors are asking the same question. The stock last closed at US$8.79, with returns of 6.4% over the past 7 days and 1.4% over the past 30 days, while the year to date return sits at a 33.5% decline. Recent coverage has focused on Wealthfront's position in diversified financials and how it fits into broader themes in automated investing and digital wealth management. This...

XPeng has launched its second generation Vision Language Action smart driving system, VLA 2.0, aimed at fully autonomous driving capabilities. Volkswagen will be the first external customer for VLA 2.0, marking a new technology partnership between the two automakers. XPeng plans to roll out fully autonomous robotaxis powered by VLA 2.0 as part of its commercial push in AI driven mobility. XPeng, listed as NYSE:XPEV, is putting this move in front of investors at a time when its share price...

In early March 2026, Helus Pharma, a Cybin company, reported positive topline Phase 2 results for HLP004 as an adjunctive treatment for adults with moderate-to-severe generalized anxiety disorder who remained symptomatic despite standard antidepressant therapy, showing clinically meaningful anxiety score reductions, durable response and remission rates, and a favorable tolerability profile. The findings highlight HLP004’s commercially practical intramuscular administration with short...

Life Time Group Holdings (NYSE:LTH) has approved a new $500 million share repurchase program. The buyback plan targets the company's common stock and is intended to support long term shareholder value. This authorization adds a fresh capital allocation lever for the fitness and lifestyle operator. Life Time Group Holdings, trading at $26.12 per share, is coming off a mixed share price run, with a 51.2% gain over three years but a 13.3% decline over the past year. In the shorter term, the...

CRISPR Therapeutics reported a threefold increase in Casgevy patient initiations for sickle cell disease and beta thalassemia over the past year. The company highlighted ongoing commercial rollout progress alongside continued net losses. Management pointed to a strong cash position as support for both Casgevy expansion and further R&D. CRISPR Therapeutics, trading on NasdaqGM:CRSP, is in the spotlight as Casgevy gains early traction in the gene therapy market. The stock closed at $57.33,...

In late February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million with a quarterly net loss of US$108.12 million, and around the same time filed a US$300 million at-the-market follow-on equity offering plus a US$68.57 million shelf registration tied to an ESOP. Shortly after these filings, Director Blake Borgeson sold 170,000 Class A shares while still retaining more than 6.25 million shares, drawing attention to insider sentiment alongside the...

Event overview and why NRG Energy is on investors’ radar NRG Energy (NRG) has attracted fresh attention after a strong 1 year total return of 78.24%, standing out against more muted recent moves over the past week and month. That contrast between short term pullback and longer term strength is prompting investors to reassess how the company’s US$30,713.0m in revenue and US$797.0m in net income line up with current pricing. See our latest analysis for NRG Energy. At a share price of US$160.46,...

Assessing Acushnet Holdings after recent share price moves Acushnet Holdings (GOLF) has recently seen mixed share price performance, with a 2.3% decline over the past day and a 5.6% decline over the past week, alongside gains over the past 3 months and year. See our latest analysis for Acushnet Holdings. Putting that into context, the recent 1-day and 7-day share price declines sit against a stronger 90-day share price return of 16.4% and a 1-year total shareholder return of 44.0%. This...

JBS stock snapshot and recent performance JBS (NYSE:JBS) has recently drawn investor attention as its shares trade around $15.65, with returns showing mixed short term moves and a positive shift over the past 3 months and year to date. See our latest analysis for JBS. Despite a recent 1-day share price return decline of 4.16% and a 7-day share price return decline of 5.89%, JBS still shows a 90-day share price return of 9.06% and a year to date share price return of 10.37%. This suggests...

Oil price shock and inflation fears hit Atmus Filtration Technologies (ATMU) Atmus Filtration Technologies (ATMU) came under pressure after crude oil prices jumped on escalating conflict with Iran, raising concerns about renewed inflation and the prospect of more challenging central bank interest rate decisions. See our latest analysis for Atmus Filtration Technologies. Despite the latest 2.97% 1 day share price decline to $61.84, Atmus Filtration Technologies still has a 1 month share price...

Huntington Bancshares at a glance Huntington Bancshares (HBAN) has drawn attention after recent share price weakness, with the stock down about 9% over the past month and modestly lower over the past 3 months. At a last close of $16.68, the regional bank carries a value score of 3 and reports annual revenue of $7,692.0 and net income of $2,087.0, both stated with positive annual growth rates. See our latest analysis for Huntington Bancshares. The recent 9.3% 30 day share price decline and...

Zoom Communications (ZM) is back in focus after a sector wide rally spotlighted enterprise software names, just days after the company reported quarterly results that exceeded its guidance midpoint for a third straight time. See our latest analysis for Zoom Communications. Even after the sector rally and the latest earnings beat, Zoom’s share price of US$77.33 sits below its recent highs, with a 30 day share price return of 12.85% decline and a year to date share price return of 7.19%...